Stay updated on ACTT: Remdesivir for Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.

Latest updates to the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page
- Check5 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, signaling a minor update to the documentation or UI without substantive changes to the study information.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision label in the Study Documents area was updated from v3.6.3 to v3.6.4, indicating a newer version of the protocol document is now referenced.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous v3.6.0. This indicates a patch-level update to the page's revision history without altering the core content of the study details.SummaryDifference0.0%

- Check55 days agoChange Detected- Added a new publication reference (Lin et al.) to the study record. This article discusses evaluating treatment efficacy in hospitalized COVID-19 patients and its applications to Adaptive COVID-19 Treatment Trials, expanding the record's related literature.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page now shows 'No longer looking for participants' to signal enrollment is closed, and it adds guidance sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', while updating the revision stamp to v3.6.0 and adjusting the Intervention/Treatment heading.SummaryDifference0.3%

- Check69 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates an updated version of the associated document on the page.SummaryDifference0.0%

Stay in the know with updates to ACTT: Remdesivir for Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.